Search Results
Nov 08, 2025, 10:40 ET Clinically meaningful pivotal study results for olezarsen in sHTG presented as a late breaker at AHA Scientific Sessions
partnershipOlezarsen is an investigational RNA-targeted medicine being evaluated for the treatment of sHTG. Olezarsen is designed to lower the body's production of apoC-III, a protein produced in the liver that regulates triglyceride metabolism in the blood. Olezarsen is approved in the U.S. and the European Union as TRYNGOLZA®
More news about: Swedish Orphan Biovitrum AB
Nov 08, 2025, 08:30 ET AusperBio Announces Late-Breaking 48-Week Phase II Data of AHB-137 in Chronic Hepatitis B at AASLD 2025
(2025). This novel dual-mechanism ASO has completed a global Phase I study and is currently being evaluated in multiple Phase II studies and a phase III trial in China. Supported by a coordinated global development strategy, AHB-137 is advancing toward its goal of delivering a potential functional cure
More news about: AusperBio Therapeutics Inc.
Nov 08, 2025, 01:42 ET DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Jasper
studies would be confounded, thereby negatively impacting the regulatory and commercial prospects of the Company's products, including briquilimab; (iii) the foregoing increased the likelihood of disruptive cost-reduction measures; (iv) accordingly, the Company's business and/or financial prospects, as
More news about: Faruqi & Faruqi, LLP
Nov 07, 2025, 23:59 ET MLTX INVESTOR DEADLINE: MoonLake Immunotherapeutics Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit
IL-17F); (ii) SLK's distinct Nanobody structure would not confer a superior clinical benefit over the traditional monoclonal structure of BIMZELX; and (iii) SLK's distinct Nanobody structure supposed increased tissue penetration would not translate to clinical efficacy. The MoonLake
More news about: Robbins Geller Rudman & Dowd LLP
Nov 07, 2025, 21:32 ET Pfizer and Metsera Enter into Merger Agreement Amendment; Metsera's Board of Directors Reaffirms Support of Merger with Pfizer
from stockholders of Metsera in favor of the proposed transaction. Information about Metsera's directors and executive officers is set forth in Part III of Metsera's Annual Report on Form 10-K for the fiscal year ended December 31, 2024, which was filed with the SEC on March 26, 2025. Additional information
More news about: Metsera, Inc.
Nov 07, 2025, 16:05 ET Lazydays Announces Plan to Delist from Nasdaq
foreseeable future; (ii) our substantial secured and unsecured indebtedness and outstanding trade payables, and our inability to refinance such indebtedness; (iii) the fact that the Asset Sale is the result of an active, lengthy and thorough evaluation and negotiation of strategic alternatives reasonably available
More news about: Lazydays RV
Nov 07, 2025, 16:00 ET Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Savara Inc.(SVRA) Shareholders
regarding MOLBREEVI's chemistry, manufacturing, and/or controls; (ii) accordingly, FDA was unlikely to approve the MOLBREEVI BLA in its current form; (iii) foregoing made it unlikely that Savara would complete its submission of the MOLBREEVI BLA within the timeframe it had represented to investors; (iv)
More news about: Levi & Korsinsky, LLP
Nov 07, 2025, 16:00 ET FLR LAWSUIT ALERT: Levi & Korsinsky Notifies Fluor Corporation Investors of a Class Action Lawsuit and Upcoming Deadline
hesitation around economic uncertainty, was having, or was likely to have, a significant negative impact on the Company's business and financial results; (iii) accordingly, Fluor's financial guidance for FY 2025 was unreliable and/or unrealistic, the effectiveness of the Company's risk mitigation strategy was
More news about: Levi & Korsinsky, LLP
Nov 07, 2025, 16:00 ET DexCom, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before December 26, 2025 to Discuss Your Rights - DXCM
and G7 less reliable than their prior iterations, presenting a material health risk to users relying on those devices for accurate glucose readings; (iii) accordingly, defendants' purported enhancements to the G7, as well as the device's reliability, accuracy, and functionality, were overstated; (iv) defendants
More news about: Levi & Korsinsky, LLP
Nov 07, 2025, 15:21 ET Whiteford Taylor & Preston, in partnership with Peterson Law, is representing several Kentucky families and businesses to file a lawsuit against UPS and others following the Louisville Plane Crash
The firms' legal team—led by Masten Childers III, Managing Partner of Whiteford's Kentucky offices, and Justin Peterson, Founding Partner of Peterson Law —are leading the aggressive representation
More news about: Peterson Law
Nov 07, 2025, 11:30 ET Ivonescimab HARMONi-A Study Final OS Analysis Results Presented at SITC 2025 with OS HR=0.74
Phase III clinical trial of an immunotherapy in the EGFR-TKI resistant, EGFR-mutated nsq-NSCLC setting to demonstrate clinically meaningful and statistically significant benefits in both Progression-Free Survival (PFS) and Overall Survival (OS). This final OS analysis, the first from a Phase III trial
More news about: Akeso, Inc.
Nov 07, 2025, 10:26 ET DOST and The Hashgraph Group Sign Collaboration Agreement to Advance Web3 Innovation in the Philippines
agreements with the first six of 17 administrative regions, which included National Capital Region, Cordillera Administrative Region, Regional Office III – Central Luzon, Regional Office VI – Western Visayas, Regional Office VIII – Eastern Visayas, and Regional Office XI – Davao.
More news about: The Hashgraph Group (THG)
Nov 07, 2025, 09:00 ET Spirit Airlines Reaches Agreements with Pilots and Flight Attendants as it Continues to Advance its Restructuring
after the date of such statements. Risks or uncertainties (i) that are not currently known to us, (ii) that we currently deem to be immaterial, or (iii) that could apply to any company, could also materially adversely affect our business, financial condition, or future results. Additional information
More news about: Spirit Airlines
Nov 07, 2025, 07:00 ET THE WENDY'S COMPANY REPORTS THIRD QUARTER 2025 RESULTS
free cash flow as cash flows from operations minus (i) capital expenditures, (ii) expenditures related to the Company's franchise development fund and (iii) the net change in the restricted operating assets and liabilities of the advertising funds and any excess/deficit of advertising funds revenue over
More news about: The Wendy’s Company
Nov 07, 2025, 07:00 ET Calumet Reports Third Quarter 2025 Results
regarding our business outlook and cash flows, including with respect to the Montana Renewables business and our plans to de-leverage our balance sheet, (iii) our ability to monetize PTCs and the price we expect to receive for PTCs, (iv) our expectation regarding anticipated capital expenditures and strategic
More news about: Calumet, Inc.
Nov 07, 2025, 06:45 ET TELUS reports strong operational and financial results for third quarter 2025
automation subscriber growth; (iii) higher external revenues in TELUS Digital; and (iv) higher residential internet revenue per customer. These factors were partially offset by: (i) lower mobile phone ARPU; (ii) lower business-to-business (B2B) data services revenue; (iii) lower agriculture and consumer
More news about: TELUS Corporation
Nov 07, 2025, 02:50 ET The Board of Directors in SciBase resolves on an offer to repurchase outstanding warrants of series TO 2 and intends to resolve on a rights issue of shares of approximately SEK 83 million
person on whose behalf the investor is acting, directly or indirectly, would hold 10 percent or more of the total voting rights in the Company; and iii) the investor, any member of its ownership structure or any person on whose behalf the investor is acting, would acquire through the investment a direct
More news about: SciBase
Nov 06, 2025, 21:59 ET NEW YORK CITY'S ICONIC PALEY MUSEUM, WHERE MEDIA, SPORTS, GAMING & ENTERTAINMENT COME TOGETHER, LAUNCHES ITS 50TH ANNIVERSARY
immersive, dynamic audience experience. The naming of the George J. Gillespie, III Theater is made possible by William S. Paley Foundation, in honor of George J. Gillespie III, the highly respected attorney, philanthropist, and dedicated leader who served nearly three decades on
More news about: The Paley Center for Media
Nov 06, 2025, 19:12 ET FIRST FINANCIAL BANCORP. ANNOUNCES PRICING OF SUBORDINATED NOTES OFFERING
economic growth; our capital and liquidity requirements (including under regulatory capital standards, such as the Basel III capital standards) and our ability to generate capital internally or raise capital on favorable terms; financial services
More news about: First Financial Bancorp.
Nov 06, 2025, 18:44 ET Wheaton Precious Metals Announces Record Revenue, Earnings and Cash Flow for the First Nine Months of 2025
Refer to discussion on non-GAAP measure (iii) at the end of this press release.
More news about: Wheaton Precious Metals Corp.
Nov 06, 2025, 18:34 ET SILVERCORP REPORTS ADJUSTED NET INCOME OF $22.6 MILLION, $0.10 PER SHARE, AND CASH FLOW FROM OPERATING ACTIVITIES OF $39.2 MILLION FOR Q2 FISCAL 2026
expenditures; ii) an increase of $1.4 million in mineral rights royalty, implemented by the Chinese authorities in the third quarter of Fiscal 2025; and iii) the increase in cash cost per ounce of silver, partially offset by a decrease of $1.6 million in general administrative expenses.
More news about: Silvercorp Metals Inc.
Nov 06, 2025, 18:30 ET Breakwater Energy Holdings S.à r.l. Announces Pricing of Offering of Senior Secured Notes Due 2030
within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the "Financial Promotion Order")), (iii) fall within Article 49(2)(a) to (d) ("high net worth companies, unincorporated associations, etc.") of the Financial Promotion Order, or (iv) are persons
More news about: Breakwater Energy
Nov 06, 2025, 18:30 ET Breakwater Energy Holdings S.à r.l. Announces Pricing of Offering of Senior Secured Notes Due 2030
within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the "Financial Promotion Order")), (iii) fall within Article 49(2)(a) to (d) ("high net worth companies, unincorporated associations, etc.") of the Financial Promotion Order, or (iv) are persons
More news about: Breakwater Energy
Nov 06, 2025, 17:31 ET Endometrial Cancer Market Poised for Expansion Throughout Forecast Period (2025-2034) Amid Increasing Adoption of Immunotherapies | DelveInsight
sparing normal cells. Selinexor is being assessed in a Phase III clinical trial (SIENDO study) as a maintenance therapy compared to placebo in patients with endometrial cancer following first- or second-line chemotherapy. Another Phase III trial (XPORT-EC-042) is investigating its use as maintenance
More news about: DelveInsight Business Research, LLP
Nov 06, 2025, 17:15 ET i-80 Gold Announces High-Grade Mineral Resource Estimate for the FAD Project and Confirms Near-Surface Oxide Mineralization
to be inaccurate. Mineral resource estimates may have to be re-estimated based on: (i) fluctuations in commodities prices; (ii) results of drilling, (iii) metallurgical testing and other studies; (iv) proposed mining operations, including dilution; (v) the evaluation of mine plans subsequent to the date
More news about: i-80 Gold Corp